Abstract
Centenarians don’t just live longer — their immune systems seem to age on a different, gentler curve. For more than a decade, researchers have traced part of that resilience to a single gene: BPIFB4, and specifically to a longevity-associated variant of it, known as LAV-BPIFB4. Carriers of this variant show lower cardiovascular risk, reduced chronic inflammation, and — as a growing body of work has shown — measurably better-aging immune function.
What has been missing, until now, is a clear answer to the question every clinician and scientist eventually asks: through what mechanism? A study just published in Aging Cell (“The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity,” 2026) gives us one of the clearest answers yet — and it points to a cell type that rarely gets credit for anything beyond clotting: the platelet.
A Quick Refresher: What Is LAV-BPIFB4?
BPIFB4 is a gene identified through genome-wide studies of long-living individuals across multiple, geographically distinct centenarian cohorts. The “LAV” — Longevity-Associated Variant — carries four specific amino acid substitutions that distinguish it from the more common wild-type form. Prior research has already linked LAV-BPIFB4 to improved vascular function, better nitric oxide availability, protection against cardiac ischemia, and a calmer, better-regulated immune system in aging tissue.
What the new study adds is a specific, testable cellular mechanism for the immune side of that story.
The New Finding: Platelets as Immune Messengers
Platelets are best known for clotting, but they are also active signaling cells that circulate constantly and interact with the immune system. The new research shows that LAV-BPIFB4 reshapes platelets at the surface level by increasing their expression of CD47, a protein that platelets use to communicate “do not attack” and “calm down” signals to nearby immune cells, particularly monocytes.
In practical terms: platelets carrying more CD47 on their surface are able to quiet an overactive, inflamed monocyte response — one of the hallmarks of chronic low-grade inflammation (“inflammaging”) that accumulates with age.
What the Data Actually Shows
Blast is committed to representing findings precisely, so it’s worth being clear about which results come from humans and which come from preclinical models:
Human, observational: Centenarians show a higher percentage of circulating CD47-positive reticulated (newly formed) platelets than younger comparison groups. This same pattern was independently seen in LAV-BPIFB4 gene carriers of any age.
Human, functional (ex vivo): Platelets isolated from LAV-BPIFB4 carriers suppressed monocyte activation and inflammatory cytokine release when challenged in the lab, acting through CD47-dependent signaling and selectively dampening p38 MAPK activity while leaving NF-κB signaling largely intact.
Cell model, in vitro: Human megakaryoblastic cells engineered to overexpress LAV-BPIFB4 produced more CD47-high, platelet-like particles, showing the effect originates during platelet production itself.
Mouse, in vivo: Administering recombinant LAV-BPIFB4 protein to mice increased CD47 on their platelets and reduced inflammatory monocyte activation when those platelets were later challenged ex vivo — demonstrating the effect is inducible, not just a fixed genetic trait, and that it translates across species.
Together, this is genetic/observational human evidence paired with mechanistic and interventional confirmation in cell and animal models — precisely the kind of layered evidence base that gives a longevity mechanism real credibility.
Why This Fits the Bigger Cardiovascular Picture
It helps to zoom out for a moment. Atherosclerotic plaque — the buildup that narrows arteries and eventually drives heart attacks and strokes — has never been a purely mechanical, “pipes clogging up” problem. It is, at its core, an immune process. Circulating monocytes get recruited into the vessel wall, differentiate into macrophages, and — when chronic inflammatory signaling keeps them switched on — accumulate as the foam cells and inflammatory infiltrate that make plaque grow and, more dangerously, become unstable.
That is exactly the pathway this new mechanism reaches into. By increasing CD47 on platelets, LAV-BPIFB4 quiets the same monocyte activation that feeds macrophage recruitment into the vessel wall. So this isn’t a separate, unrelated benefit sitting alongside the gene’s known vascular effects — it’s a second entry point into the same underlying process, addressing the immune root of plaque formation rather than only its downstream vascular consequences.
Why This Matters for a Gene Therapy Program
This finding matters because it reframes LAV-BPIFB4 not just as a cardiovascular-protective gene, but as an immune-recalibrating one — with a defined molecular handle (the CD47 axis) that can eventually be measured and monitored. For a therapy built on delivering the LAV variant of this gene, that’s a meaningful piece of the story: it helps explain, at the level of a single cell-surface protein, why carriers of this longevity variant seem to weather the low-grade inflammatory drift of aging so much better than most.
It’s also a useful example of the Foundation philosophy that guides everything we build at Blast: this is not a claim about defying biology or extending intrinsic lifespan. It’s about restoring and reinforcing a homeostatic mechanism nature has already shown works — one that long-living individuals carry naturally, and that gene therapy may be able to extend to others while the next generation of longevity science continues to unfold.
Reference: The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity. Aging Cell, 2026. https://doi.org/10.1111/acel.70602
